Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study

Published on Dec 1, 2019in Lancet Neurology28.755
· DOI :10.1016/S1474-4422(19)30354-0
Emma L. van der Ende4
Estimated H-index: 4
(EUR: Erasmus University Rotterdam),
Lieke H.H. Meeter8
Estimated H-index: 8
(EUR: Erasmus University Rotterdam)
+ 40 AuthorsJohn C. van Swieten53
Estimated H-index: 53
(EUR: Erasmus University Rotterdam)
Summary Background Neurofilament light chain (NfL) is a promising blood biomarker in genetic frontotemporal dementia, with elevated concentrations in symptomatic carriers of mutations in GRN, C9orf72, and MAPT. A better understanding of NfL dynamics is essential for upcoming therapeutic trials. We aimed to study longitudinal NfL trajectories in people with presymptomatic and symptomatic genetic frontotemporal dementia. Methods We recruited participants from 14 centres collaborating in the Genetic Frontotemporal Dementia Initiative (GENFI), which is a multicentre cohort study of families with genetic frontotemporal dementia done across Europe and Canada. Eligible participants (aged ≥18 years) either had frontotemporal dementia due to a pathogenic mutation in GRN, C9orf72, or MAPT (symptomatic mutation carriers) or were healthy at-risk first-degree relatives (either presymptomatic mutation carriers or non-carriers), and had at least two serum samples with a time interval of 6 months or more. Participants were excluded if they had neurological comorbidities that were likely to affect NfL, including cerebrovascular events. We measured NfL longitudinally in serum samples collected between June 8, 2012, and Dec 8, 2017, through follow-up visits annually or every 2 years, which also included MRI and neuropsychological assessments. Using mixed-effects models, we analysed NfL changes over time and correlated them with longitudinal imaging and clinical parameters, controlling for age, sex, and study site. The primary outcome was the course of NfL over time in the various stages of genetic frontotemporal dementia. Findings We included 59 symptomatic carriers and 149 presymptomatic carriers of a mutation in GRN, C9orf72, or MAPT, and 127 non-carriers. Nine presymptomatic carriers became symptomatic during follow-up (so-called converters). Baseline NfL was elevated in symptomatic carriers (median 52 pg/mL [IQR 24–69]) compared with presymptomatic carriers (9 pg/mL [6–13]; p Interpretation Our findings show the value of blood NfL as a disease progression biomarker in genetic frontotemporal dementia and suggest that longitudinal NfL measurements could identify mutation carriers approaching symptom onset and capture rates of brain atrophy. The characterisation of NfL over the course of disease provides valuable information for its use as a treatment effect marker. Funding ZonMw and the Bluefield project.
  • References (31)
  • Citations (3)
📖 Papers frequently viewed together
2 Citations
17 Authors (Philip S.J. Weston, ..., Nick C. Fox)
50 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Philip S.J. Weston (UCL Institute of Neurology)H-Index: 12
#2Teresa Poole (UCL Institute of Neurology)H-Index: 4
Last. Nick C. Fox (UCL Institute of Neurology)H-Index: 115
view all 13 authors...
2 CitationsSource
#1Niklas Mattsson (Lund University)H-Index: 44
#2Nicholas C. Cullen (UPenn: University of Pennsylvania)H-Index: 5
Last. Kaj Blennow (University of Gothenburg)H-Index: 123
view all 5 authors...
Importance: Plasma neurofilament light (NfL) has been suggested as a noninvasive biomarker to monitor neurodegeneration in Alzheimer disease (AD), but studies are lacking. Objective: To examine whether longitudinal plasma NfL levels are associated with other hallmarks of AD. Design, Setting, and Participants: This North American cohort study used data from 1583 individuals in the multicenter Alzheimer's Disease Neuroimaging Initiative study from September 7, 2005, through June 16, 2016. Patients...
17 CitationsSource
#1Kristin N. Varhaug (University of Bergen)H-Index: 2
#2Øivind Torkildsen (University of Bergen)H-Index: 22
Last. Christian A. Vedeler (University of Bergen)H-Index: 34
view all 4 authors...
Due to the unpredictable course and heterogenous treatment response in multiple sclerosis (MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up of these patients. Neurofilaments are neuron-specific components of the cytoskeleton that can be assayed in different body compartments. They have been explored as potential biomarkers for many years. Neurofilament light chain (NF-L) appears the most promising biomarker in MS patients, and there is now little ...
#1Oliver Preische (University of Tübingen)H-Index: 8
#2Stephanie A. Schultz (WashU: Washington University in St. Louis)H-Index: 12
Last. Mathias Jucker (University of Tübingen)H-Index: 49
view all 31 authors...
Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly Inherited Alzheimer Network and ultrasensitive immunoassay technology to demonstrate that NfL levels in the cerebrospinal fluid (n = 187) and serum (n = 405) are correlated with one another and are elevated at the presymptomatic stages of familial Alzheimer’s disease. Longitudinal, within-person analysis of serum N...
28 CitationsSource
#1Federico VerdeH-Index: 9
#2Petra Steinacker (University of Ulm)H-Index: 29
Last. Markus Otto (University of Ulm)H-Index: 61
view all 18 authors...
Objective To determine the diagnostic and prognostic performance of serum neurofilament light chain (NFL) in amyotrophic lateral sclerosis (ALS). Methods This single-centre, prospective, longitudinal study included the following patients: 124 patients with ALS; 50 patients without neurodegenerative diseases; 44 patients with conditions included in the differential diagnosis of ALS (disease controls); 65 patients with other neurodegenerative diseases (20 with frontotemporal dementia, 20 with Alzh...
12 CitationsSource
#1Joery Goossens (University of Antwerp)H-Index: 6
#2Maria Bjerke (University of Antwerp)H-Index: 23
Last. Sebastiaan Engelborghs (University of Antwerp)H-Index: 65
view all 13 authors...
Background We explored the diagnostic performance of cerebrospinal fluid (CSF) biomarkers in allowing differentiation between frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD), as well as between FTLD pathological subtypes.
11 CitationsSource
#1Petra SteinackerH-Index: 29
Last. Markus OttoH-Index: 61
view all 28 authors...
Objective To determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD). Methods Blood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed for the diagnostic potential in relation to functional assessment (Clinica...
5 CitationsSource
#1Michael Khalil (Medical University of Graz)H-Index: 27
#2Charlotte E. Teunissen (UvA: University of Amsterdam)H-Index: 3
Last. Jens Kuhle (University of Basel)H-Index: 43
view all 14 authors...
Neuroaxonal damage is the pathological substrate of permanent disability in various neurological disorders. Reliable quantification and longitudinal follow-up of such damage are important for assessing disease activity, monitoring treatment responses, facilitating treatment development and determining prognosis. The neurofilament proteins have promise in this context because their levels rise upon neuroaxonal damage not only in the cerebrospinal fluid (CSF) but also in blood, and they indicate n...
74 CitationsSource
#1Michael G Benatar (UM: University of Miami)H-Index: 32
#2Joanne Wuu (UM: University of Miami)H-Index: 40
Last. Andrea Malaspina (QMUL: Queen Mary University of London)H-Index: 29
view all 5 authors...
Objective: To evaluate neurofilament light (NfL) as a biomarker of the presymptomatic phase of amyotrophic lateral sclerosis (ALS).Methods: The study population includes 84 individuals at risk for ...
22 CitationsSource
#1Babykumari P. Chitramuthu (MUHC: McGill University Health Centre)H-Index: 8
#2Hugh P. J. Bennett (MUHC: McGill University Health Centre)H-Index: 33
Last. Andrew Bateman (MUHC: McGill University Health Centre)H-Index: 5
view all 3 authors...
19 CitationsSource
Cited By3
#1Henrik ZetterbergH-Index: 90
#2Elena BozzettaH-Index: 12
Last. Daniela MeloniH-Index: 5
view all 9 authors...
Scrapie is a fatal neurodegenerative disease of sheep and goats belonging to the group of Transmissible Spongiform Encephalopathy or prion diseases. The EU has adopted mandatory measures for scrapie surveillance to safeguard public and animal health because it is highly contagious and might decimate all genetic susceptible animals in affected flocks. Definite diagnosis of scrapie relies on the detection of the pathological prion protein in brain tissues and there are still no blood biomarkers av...
#1Lucilla Parnetti (University of Perugia)H-Index: 50
#2Lorenzo Gaetani (University of Perugia)H-Index: 6
Last. Massimiliano Di Filippo (University of Perugia)H-Index: 27
view all 3 authors...